Across TCGA pan-cancer cohorts, ZNF565 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF565 data layer compared with 25 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher ZNF565 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF565 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

LIHC, CESC, and BLCA are the cancer types where ZNF565 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.082	0.786	<.001	30	view →
CESC	OS	Median	II,III,IV	0.047	0.830	<.001	18	view →
BLCA	DFS	Median	All	1.000	0.325	.025	14	view →
UCEC	DFS	Median	II,III,IV	0.922	0.436	.022	14	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZNF565 tumor-vs-normal RNA expression · all ZNF565 data types